Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Nivolumab in Advanced Solid Tumors
NCT04704154Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), pancreatic ductal adenocarcinoma (PDAC) and 3 more, sponsored by Bayer. Primary endpoint: Overall Response Rate at 26 months. Started Feb 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)pancreatic ductal adenocarcinoma (PDAC)biliary tract carcinoma (BTC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04704154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704154.